Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Tumor cells gene-modified to produce GM-CSF potently stimulate antitumor immune responses, in part, by causing the growth and differentiation of dendritic cells (DC). However, GM-CSF-modified tumor cells must be gamma-irradiated or they will grow progressively, killing the host. We observed that 23 of 75 (31%) human tumor lines and two commonly used mouse tumor lines spontaneously produced GM-CSF. In mice, chronic GM-CSF production by tumors suppressed Ag-specific CD8+ T cell responses. Interestingly, an inhibitory population of adherent CD11b(Mac-1)/Gr-1 double-positive cells caused the observed impairment of CD8+ T cell function upon direct cell-to-cell contact. The inhibitory cells were positive for some markers associated with Ag presenting cells, like F4/80, but were negative for markers associated with fully mature DC like DEC205, B7. 2, and MHC class II. We have previously reported that a similar or identical population of inhibitory "immature" APC was elicited after immunization with powerful recombinant immunogens. We show here that these inhibitory cells can be elicited by the administration of recombinant GM-CSF alone, and, furthermore, that they can be differentiated ex vivo into "mature" APC by the addition of IL-4 and GM-CSF. Thus, tumors may be able to escape from immune detection by producing "unopposed" GM-CSF, thereby disrupting the balance of cytokines needed for the maturation of fully functional DC. Further, CD11b/Gr-1 double-positive cells may function as "inhibitory" APC under the influence of GM-CSF alone.

[1]  S. Rosenberg,et al.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand. , 1999, Cancer research.

[2]  O. Majdic,et al.  Neutrophil Granulocyte–committed Cells Can Be Driven to Acquire Dendritic Cell Characteristics , 1998, The Journal of experimental medicine.

[3]  P. Lollini,et al.  Colony-stimulating activity from the new metastatic TS/A cell line and its high- and low-metastatic clonal derivatives. , 1985, British Journal of Cancer.

[4]  P. Hersey,et al.  Production of IL‐10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma , 1994, International journal of cancer.

[5]  E. Jaffee,et al.  Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. , 1998, Human gene therapy.

[6]  S. Rosenberg,et al.  Developing recombinant and synthetic vaccines for the treatment of melanoma. , 1999, Current opinion in oncology.

[7]  T. Starzl,et al.  Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. , 1995, Transplantation.

[8]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[9]  E. Maraskovsky,et al.  Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified , 1996, The Journal of experimental medicine.

[10]  F. Marincola,et al.  Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Steinman,et al.  Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Blankenstein,et al.  Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. , 1997, Journal of immunology.

[13]  R. Kirken,et al.  Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes. , 1997, Journal of immunology.

[14]  E. Jaffee,et al.  Cancer Vaccines , 1997, Current protocols in human genetics.

[15]  K. Takeda,et al.  A correlation between GM‐CSF gene expression and metastases in murine tumors , 1991, International journal of cancer.

[16]  R. Suzuki,et al.  Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. , 1988, Journal of immunology.

[17]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[18]  R. Steinman,et al.  Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells , 1987, The Journal of experimental medicine.

[19]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[20]  A. Chinnaiyan,et al.  Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death , 1997, Science.

[21]  J. Griffith,et al.  GM-CSF secretion in primary cultures of normal and cancerous human renal cells. , 1996, Kidney international.

[22]  Antonio Lanzavecchia,et al.  Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells , 1997, Nature.

[23]  T. Kocher,et al.  FLT3 ligand gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens , 1998, International journal of cancer.

[24]  K. Shortman,et al.  A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand- induced apoptosis , 1996, The Journal of experimental medicine.

[25]  S. Rosenberg,et al.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. , 1995, Journal of immunology.

[26]  F. Marincola,et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.

[27]  D. Bigner,et al.  Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.

[28]  S. Rosenberg,et al.  Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. , 1998, Journal of immunology.

[29]  S. Rosenberg,et al.  Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. , 1997, Journal of the National Cancer Institute.

[30]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[31]  D. Pardoll,et al.  A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours , 1995, Nature Medicine.

[32]  R. Steinman,et al.  Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Rosenberg,et al.  Route of immunization and the therapeutic impact of recombinant anticancer vaccines. , 1997, Journal of the National Cancer Institute.

[34]  N. Restifo,et al.  T cell–tumor cell: a fatal interaction? , 1998, Cancer Immunology, Immunotherapy.

[35]  Jonathan J. Lewis,et al.  Heteroclitic Immunization Induces Tumor Immunity , 1998, The Journal of experimental medicine.

[36]  G. Kaplan,et al.  The distinctive features of influenza virus infection of dendritic cells. , 1998, Immunobiology.

[37]  P. Cohen,et al.  Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Blay,et al.  The host-tumor immune conflict: from immunosuppression to resistance and destruction. , 1997, Immunology today.

[39]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[40]  M. Cohen,et al.  Human prostate carcinoma cell lines secrete GM-CSF and express GM-CSF-receptor on their cell surface. , 1996, Anticancer research.

[41]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[42]  M. Bevan,et al.  Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. , 1993, Journal of immunology.

[43]  A. Kelso,et al.  A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. , 1996, Journal of immunology.

[44]  P. Musiani,et al.  Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. , 1995, Journal of immunology.

[45]  D. Longo,et al.  Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. , 1996, Journal of immunology.

[46]  A. Dunn,et al.  The influence of granulocyte/macrophage colony‐stimulating factor on dendritic cell levels in mouse lymphoid organs , 1997, European journal of immunology.

[47]  S. Rosenberg,et al.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.

[48]  R. Steinman,et al.  The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing , 1995, Nature.

[49]  J. Becker,et al.  Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. , 1995, Melanoma research.

[50]  N. Restifo,et al.  Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. , 1997, Methods.

[51]  B. Moss,et al.  Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[52]  L. Terracciano,et al.  GM‐CSF gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens , 1998, International journal of cancer.

[53]  G. Nabel,et al.  Mechanisms of Tumor-Induced Immunosuppression: Evidence for Contact-Dependent T Cell Suppression by Monocytes , 1996, Molecular medicine.

[54]  R. Bast,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. , 1988, The New England journal of medicine.

[55]  Freddie H. Fu,et al.  Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. , 1996, Transplantation.

[56]  N. Restifo Cancer Vaccines '98: a reductionistic approach , 1998 .

[57]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Loise M. Francisco,et al.  Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.

[59]  R. Germain,et al.  Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization , 1998, The Journal of experimental medicine.

[60]  S. Rosenberg,et al.  Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. , 1998, Virology.

[61]  P. Henkart,et al.  Different Interleukin-1β Converting Enzyme (ICE) Family Protease Requirements for the Apoptotic Death of T Lymphocytes Triggered by Diverse Stimuli , 1996, The Journal of experimental medicine.

[62]  R. Steinman,et al.  Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.

[63]  José Luis de la Pompa,et al.  Differential Requirement for Caspase 9 in Apoptotic Pathways In Vivo , 1998, Cell.